Pyxis Oncology, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Pyxis Oncology, Inc. (PYXS) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$1.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- Pyxis Oncology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$816.00K, a 151.88% decline year-over-year.
- Pyxis Oncology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$694.00K, a 174.62% decline year-over-year.
- Pyxis Oncology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$1.57M, a 207.54% decline year-over-year.
- Pyxis Oncology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$1.20M.
- Pyxis Oncology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$261.00K, a 228.57% decline from fiscal 2024.
- Pyxis Oncology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $203.00K.
- Pyxis Oncology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$2.53M, a 174.89% decline from fiscal 2022.
- Pyxis Oncology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $3.38M, a 38.34% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$816.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.51M 10-Q · filed 2026-08-13 | -$3.08M derived: sum of 3 quarters · filed 2026-08-13 | -$4.27M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$694.00K 10-Q · filed 2026-05-14 | -$2.26M derived: sum of 2 quarters · filed 2026-05-14 | -$3.46M derived: sum of 3 quarters · filed 2026-05-14 | -$1.89M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$2.76M derived: sum of 2 quarters · filed 2026-03-23 | -$1.19M derived: sum of 3 quarters · filed 2026-08-13 | -$261.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | -$1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $378.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.31M 10-Q · filed 2025-11-03 | $2.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.50M 10-Q · filed 2026-08-13 | $3.96M derived: sum of 3 quarters · filed 2026-08-13 | $2.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $930.00K 10-Q · filed 2026-05-14 | $2.39M derived: sum of 2 quarters · filed 2026-05-14 | $1.13M derived: sum of 3 quarters · filed 2026-05-14 | -$913.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $195.00K derived: sum of 2 quarters · filed 2026-03-23 | -$1.84M derived: sum of 3 quarters · filed 2026-03-23 | $203.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | -$1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$3.30M derived: sum of 2 quarters · filed 2025-11-03 | -$1.26M 10-Q · filed 2025-11-03 | -$2.08M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | -$2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $8.00K 10-Q · filed 2025-08-14 | -$812.00K derived: sum of 3 quarters · filed 2025-08-14 | -$1.85M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $2.05M 10-Q · filed 2025-05-15 | $1.23M derived: sum of 2 quarters · filed 2025-05-15 | $192.00K derived: sum of 3 quarters · filed 2025-05-15 | $0.00 derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$820.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$1.85M derived: sum of 2 quarters · filed 2025-03-18 | -$2.05M derived: sum of 3 quarters · filed 2025-03-18 | -$2.53M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$1.23M derived: sum of 2 quarters · filed 2024-11-12 | -$1.71M 10-Q · filed 2024-11-12 | $1.34M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$192.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$678.00K 10-Q · filed 2024-08-14 | $2.37M derived: sum of 3 quarters · filed 2024-08-14 | $3.40M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$486.00K 10-Q · filed 2024-05-14 | $2.56M derived: sum of 2 quarters · filed 2024-05-14 | $3.59M derived: sum of 3 quarters · filed 2024-05-14 | $2.66M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $4.08M derived: sum of 2 quarters · filed 2024-03-21 | $3.15M derived: sum of 3 quarters · filed 2024-03-21 | $3.38M 10-K · filed 2024-03-21 |
| 2022-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $100.00K derived: sum of 2 quarters · filed 2023-11-07 | $332.00K 10-Q · filed 2023-11-07 | $1.94M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$930.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$698.00K 10-Q · filed 2023-08-11 | $910.00K derived: sum of 3 quarters · filed 2023-08-11 | $1.30M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $232.00K 10-Q · filed 2023-05-11 | $1.84M derived: sum of 2 quarters · filed 2023-05-11 | $2.23M derived: sum of 3 quarters · filed 2023-05-11 | $2.60M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $2.00M derived: sum of 2 quarters · filed 2023-03-22 | $2.37M derived: sum of 3 quarters · filed 2023-03-22 | $2.44M 10-K · filed 2023-03-22 |
| 2021-09-30 | $388.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $765.00K derived: sum of 2 quarters · filed 2022-11-01 | $836.00K 10-Q · filed 2022-11-01 | $765.00K derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $377.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $448.00K 10-Q · filed 2022-08-15 | $377.00K derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | $71.00K 10-Q · filed 2022-05-13 | $0.00 derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | -$71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $13.00K 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $84.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |